• MTSEA-biotin: Identity and Evidence Boundaries

  2026-10-17

  APExBIO identifies MTSEA-biotin as catalog SKU C5669, but the available product information contains no description, structural specification, mechanism, assay context, or identity-matched research paper. The material can therefore be discussed only at the level of catalog provenance and evidence boundaries, not as a validated probe, labeling reagent, or performance-tested product.

• Thioredoxin Reductase Assay: Evidence and Scope

  2026-10-16

  The APExBIO listing identifies K2175 as a Thioredoxin Reductase Colorimetric Assay Kit, but the available product information does not document its reaction chemistry, calibration model, validation data, or research use. The product name supports a narrow interpretation: a commercial colorimetric measurement tool associated with thioredoxin reductase. It does not support claims about specific enzyme activity, biological pathway effects, clinical applicability, or comparative performance.

• MTSEA-biotin: A Proportionate Evidence Review

  2026-10-16

  APExBIO identifies MTSEA-biotin as product C5669, but the available product entry provides no description and no identity-matched research evidence is available. Accordingly, its exact chemical identity, mechanism, measurement principle, performance, and research applicability cannot be established from the documented materials.

• What WM Sequencing Evidence Says About CXCR4

  2026-10-15

  A source-grounded analysis of a 2021 Waldenström macroglobulinemia treatment-sequencing review, emphasizing genomic stratification, CXCR4 biology, comparator evidence, and the limited direct evidence for mavorixafor.

• SC 79, Akt and Ferroptosis: Evidence and Limits

  2026-10-15

  The supplied ovarian-cancer study used SC 79 as a named Akt-activating pharmacological probe while examining obacunone-associated ferroptosis. Its findings support an association among reduced Akt phosphorylation, increased p53 signaling, redox disruption and tumor-cell growth inhibition, but the available excerpt does not establish that SC 79 itself caused a defined rescue or that the Akt–p53 relationship was causally demonstrated.

• EPI-001 Evidence in AR-Driven Cancer Research

  2026-10-14

  Evidence for EPI-001 is strongest as a mechanistic and hypothesis-generating signal: a 2025 study linked AR and ARv7 expression with adverse outcomes in selected triple-negative breast cancer cohorts and reported changes in migration- and EMT-associated markers in MDA-MB-231 cells. These findings support investigation of androgen receptor N-terminal domain inhibition, but they do not establish clinical efficacy, supplier-specific equivalence, or inhibition of metastasis in patients.

• hCG, H3K27 Methylation and Decidual CXCL10

  2026-10-14

  Silasi and colleagues report that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal-cell models through EZH2-associated H3K27 trimethylation, with consequences for CD8-cell recruitment. The study supports a hormone–chromatin–chemokine relationship at the maternal–fetal interface, but it does not test GSK J4 HCl or establish JMJD3 as the causal regulator of this pathway.

• Pazopanib and ATRX-Deficient Glioma: Evidence

  2026-10-13

  A 2022 study links ATRX deficiency in high-grade glioma cells with greater sensitivity to several RTK and PDGFR inhibitors, but the evidence is class-level and does not establish pazopanib as an effective or clinically validated ATRX-selective treatment.

• Mouse Tissue Lysis Kit K1038: Evidence Overview

  2026-10-13

  The Mouse Tissue Lysis Kit (K1038), supplied by APExBIO, is documented as a research-use tissue lysis product intended to support direct PCR-based mouse genotyping. The available evidence is limited to the supplier’s product description; no matched reference paper or independent performance study was provided.

• (S)-(+)-Dimethindene Maleate: Evidence Scope

  2026-10-12

  The APExBIO product listing identifies (S)-(+)-Dimethindene maleate as a defined maleate salt described as an M2 muscarinic receptor and histamine H1 receptor antagonist. With no matched research paper available, its relevance is limited to a documented product identity and a conceptual role in receptor pharmacology—not independently verified mechanisms, outcomes, or model-specific performance.

• Reversible Biotinylation and Cell-Surface Biology

  2026-10-12

  Sulfo-NHS-SS-Biotin provides a conceptual bridge between reversible protein labeling and questions about cell-surface organization. The supplied preprint reports cell-surface RNA-binding-protein and glycoRNA nanodomains associated with TAT peptide entry, but it does not establish that this product was used or that the findings generalize across cell types.

• Sulfo-Cy7 NHS Ester Product Overview

  2026-10-10

  APExBIO lists Sulfo-Cy7 NHS Ester, SKU A8109, as a sulfonated near-infrared fluorescent dye for conceptual amino-group labeling of proteins and peptides. No matched paper evidence was supplied, so catalog specifications and application claims are not independent validation.

• DDIT4 Links Microplastics to Kidney Organoid Injury

  2026-10-09

  Wang et al. report that 1 μm polystyrene microplastics impair nephron development in human pluripotent stem cell-derived kidney organoids through a DDIT4-associated autophagy and apoptosis response. The study is notable for connecting organoid-level developmental injury with a candidate molecular mediator, while its short-term in vitro design limits direct extrapolation to human environmental exposure.

• Celastrol, CAV-1, and Mitochondrial Cholesterol

  2026-10-09

  A 2026 Phytomedicine study identifies a mechanistic link between celastrol, CAV-1/SCP2-dependent cholesterol trafficking, mitochondrial stress, and mitophagy in liver cancer models. Its findings support organelle-specific cholesterol metabolism as a research direction, while remaining preclinical and limited by the available model and reporting scope.

• NOTCH3 R545C and CADASIL Vascular-Neuronal Dysfunction

  2026-10-08

  A 2026 Neurobiology of Disease study introduces a CRISPR/Cas9-generated mouse model carrying the NOTCH3 p.R545C mutation, orthologous to the human East Asian-enriched p.R544C variant. The model links age-dependent cognitive impairment with vascular barrier disruption, neuroinflammatory signatures, synaptic dysfunction, and hippocampal structural changes, while also defining important boundaries for interpreting preclinical CADASIL evidence.

8576 records 1/572 page Next 12345 下5页 Last page